BioCentury
ARTICLE | Clinical News

KN38-7271: Phase I started

November 12, 2007 8:00 AM UTC

KeyNeurotek began a placebo-controlled, double-blind, dose-escalation Phase I trial in healthy volunteers. The company licensed the compound from BAY. ...